CN1301127C - 一种制备脉络宁注射制剂的工艺方法 - Google Patents
一种制备脉络宁注射制剂的工艺方法 Download PDFInfo
- Publication number
- CN1301127C CN1301127C CNB2004100023090A CN200410002309A CN1301127C CN 1301127 C CN1301127 C CN 1301127C CN B2004100023090 A CNB2004100023090 A CN B2004100023090A CN 200410002309 A CN200410002309 A CN 200410002309A CN 1301127 C CN1301127 C CN 1301127C
- Authority
- CN
- China
- Prior art keywords
- extract
- water
- injection
- achyranthis bidentatae
- mailuoning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007924 injection Substances 0.000 title claims abstract description 97
- 238000002347 injection Methods 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 40
- 239000009064 mailuoning Substances 0.000 claims abstract description 134
- 239000000284 extract Substances 0.000 claims description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 241000628997 Flos Species 0.000 claims description 27
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 26
- 229960003194 meglumine Drugs 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000000108 ultra-filtration Methods 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- 239000008215 water for injection Substances 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 14
- 238000012856 packing Methods 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 206010037660 Pyrexia Diseases 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 238000007689 inspection Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 230000000274 adsorptive effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 230000002879 macerating effect Effects 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 238000005325 percolation Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 4
- 239000003463 adsorbent Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 abstract description 14
- 229920001282 polysaccharide Polymers 0.000 abstract description 14
- 239000005017 polysaccharide Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 241001523681 Dendrobium Species 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 9
- 239000004615 ingredient Substances 0.000 abstract description 5
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 241000293861 Scrophularia nodosa Species 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 55
- 241000700159 Rattus Species 0.000 description 42
- 229940079593 drug Drugs 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 10
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 10
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 235000001368 chlorogenic acid Nutrition 0.000 description 10
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 10
- 229940074393 chlorogenic acid Drugs 0.000 description 10
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 10
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 206010053567 Coagulopathies Diseases 0.000 description 9
- 230000035602 clotting Effects 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 7
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 7
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 7
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 7
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 7
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 235000013985 cinnamic acid Nutrition 0.000 description 7
- 229930016911 cinnamic acid Natural products 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 238000003810 ethyl acetate extraction Methods 0.000 description 7
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 239000003978 infusion fluid Substances 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000003194 forelimb Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002267 nissl body Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000272165 Charadriidae Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 241000245240 Lonicera Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001530126 Scrophularia Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JQNVCUBPURTQPQ-UHFFFAOYSA-N (25R)-Inokosterone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(CO)C)CCC33O)C)C3=CC(=O)C21 JQNVCUBPURTQPQ-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JQNVCUBPURTQPQ-FTWMDKANSA-N Inokosterone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CC[C@H](CO)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 JQNVCUBPURTQPQ-FTWMDKANSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- XXKXGOJPDAHNGV-UHFFFAOYSA-M [Cl-].Cl[N+]=1N(N(N(C=1)C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound [Cl-].Cl[N+]=1N(N(N(C=1)C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1 XXKXGOJPDAHNGV-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- JQNVCUBPURTQPQ-XDWLXSIGSA-N inokosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(CO)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 JQNVCUBPURTQPQ-XDWLXSIGSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 230000004413 optic chiasma Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Abstract
Description
产品 | 绿元酸含量(mg/ml) | 产品 | 绿元酸含量(mg/ml) |
本发明脉络宁注射液 | 2.25 | 市售脉络宁注射液 | 0.136 |
本发明脉络宁注射液 | 2.23 | 市售脉络宁注射液 | 0.138 |
本发明脉络宁冻干粉针剂 | 2.27 | 市售脉络宁注射液 | 0.135 |
产品 | 肉桂酸含量(mg/ml) | 产品 | 肉桂酸含量(mg/ml) |
本发明脉络宁注射液 | 1.036 | 市售脉络宁注射液 | 0.536 |
本发明脉络宁注射液 | 1.104 | 市售脉络宁注射液 | 0.615 |
本发明脉络宁冻干粉针剂 | 1.122 | 市售脉络宁注射液 | 0.610 |
本发明脉络宁冻干粉针剂 | 1.134 | 市售脉络宁注射液 | 0.596 |
产品 | 蜕皮甾酮含量 | 产品 | 蜕皮甾酮含量 |
(mg/ml) | (mg/ml) | ||
本发明脉络宁注射液 | 0.1020 | 市售脉络宁注射液 | 0.0312 |
本发明脉络宁注射液 | 0.0964 | 市售脉络宁注射液 | 0.0296 |
本发明脉络宁冻干粉针剂 | 0.1082 | 市售脉络宁注射液 | 0.0415 |
本发明脉络宁冻干粉针剂 | 0.1108 | 市售脉络宁注射液 | 0.0324 |
产品 | 滨蒿内酯含量(μg/ml) | 产品 | 滨蒿内酯含量(μg/ml) |
本发明脉络宁注射液 | 9.6 | 市售脉络宁注射液 | 6.2 |
本发明脉络宁注射液 | 10.2 | 市售脉络宁注射液 | 5.9 |
本发明脉络宁冻干粉针剂 | 10.7 | 市售脉络宁注射液 | 5.8 |
本发明脉络宁冻干粉针剂 | 10.4 | 市售脉络宁注射液 | 6.0 |
组别 | 剂量(g生药/kg) | 动物数 | 分值 | |
6h | 24h | |||
假手术组MCAT模型组本发明脉络宁冻干粉针剂组市售脉络宁注射液组 | NSNS3.01.50.755.010.0 | 10151415131512 | 0±0**3.73±0.462.40±0.63**2.80±0.56**2.93±0.702.87±0.64**2.77±0.93** | 0±0**3.60±0.512.07±0.74**2.63±0.80**3.00±0.932.73±1.03**2.46±1.27** |
组别 | 剂量(mg/kg) | 动物数 | 梗塞组织重量占半脑重量的百分比(%) |
假手术组MCAT模型组本发明脉络宁冻干粉针剂组市售脉络宁注射液组 | NSNS3.01.50.755.010.0 | 10131415121312 | 0±0**8.48±4.753.51±1.17**4.48±1.31**5.22±2.34*5.35±2.22**4.11±2.74* |
组别 | 剂量(mg/kg) | 动物数 | 脑组织水含量(%) | |
左侧脑 | 右侧脑 | |||
假手术组MCAT模型组本发明脉络宁冻干粉针剂组市售脉络宁注射液组 | NSNS3.01.50.755.010.0 | 11151414141512 | 79.94±0.3379.94±0.2179.89±0.5579.79±0.1879.83±0.4979.97±0.4579.66±0.40 | 79.86±0.41**81.86±0.8380.02±0.73**80.78±0.40**81.39±0.6481.23±0.7480.48±0.73** |
组别 | 剂量(g/kg) | N | 阳性细胞面密度 |
假手术组MCAT模型组本发明脉络宁冻干粉针剂组市售脉络宁注射液组 | NSNS3.01.50.755.010.0 | 9999999 | 0.165±0.019**0.106±0.0170.148±0.026**0.141±0.020**0.131±0.015*0.135±0.018*0.141±0.028** |
组别 | 剂量(g/kg) | 出血时间(s) | 凝血时间(s) | 张口呼吸时间(s) |
假手术组MCAT模型组本发明脉络宁冻干粉针剂组市售脉络宁注射液组 | NSNS6.03.01.510.020.0 | 90.80±26.81**62.50±20.0989.67±20.81**100.73±33.57**68.93±23.48111.93±34.83**93.29±27.72** | 101.60±27.9*81.64±19.51128.60±40.96**125.00±24.32**92.43±27.72140.00±35.51**141.00±22.87** | 16.86±1.96*14.38±1.9018.00±1.78**16.86±1.99*16.07±2.2917.69±1.78**18.23±1.59** |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100023090A CN1301127C (zh) | 2004-01-07 | 2004-01-07 | 一种制备脉络宁注射制剂的工艺方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100023090A CN1301127C (zh) | 2004-01-07 | 2004-01-07 | 一种制备脉络宁注射制剂的工艺方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1555854A CN1555854A (zh) | 2004-12-22 |
CN1301127C true CN1301127C (zh) | 2007-02-21 |
Family
ID=34350702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100023090A Expired - Lifetime CN1301127C (zh) | 2004-01-07 | 2004-01-07 | 一种制备脉络宁注射制剂的工艺方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1301127C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060251739A1 (en) * | 2005-05-04 | 2006-11-09 | National Yang-Ming University | Composition and method for treating autoimmune disease and mucosal disorder |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1078148A (zh) * | 1992-12-15 | 1993-11-10 | 江苏省中医药研究所 | 脉络宁静脉注射液的工艺方法 |
CN1491688A (zh) * | 2003-07-25 | 2004-04-28 | 金陵药业股份有限公司 | 一种利用脉络宁注射液制备过程中的废弃物制备的免疫调节剂及其在制药中的应用 |
-
2004
- 2004-01-07 CN CNB2004100023090A patent/CN1301127C/zh not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1078148A (zh) * | 1992-12-15 | 1993-11-10 | 江苏省中医药研究所 | 脉络宁静脉注射液的工艺方法 |
CN1491688A (zh) * | 2003-07-25 | 2004-04-28 | 金陵药业股份有限公司 | 一种利用脉络宁注射液制备过程中的废弃物制备的免疫调节剂及其在制药中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1555854A (zh) | 2004-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1745843A (zh) | 一种抗癌中药复方制剂及其制备方法 | |
CN1733081A (zh) | 一种具有养血安神的中药制剂及其制备方法 | |
CN101053619A (zh) | 一种治疗肺纤维化的药物 | |
CN102018852B (zh) | 参连消渴降糖胶囊及制作工艺 | |
CN1301127C (zh) | 一种制备脉络宁注射制剂的工艺方法 | |
CN100509009C (zh) | 一种治疗心脑血管病、缺血性中风的中药制剂及其制备方法 | |
CN1853689A (zh) | 一种治疗心脑血管病的中药制剂及其制备方法 | |
CN1297288C (zh) | 一种治疗心血管疾病的药物及其制备方法 | |
CN1293901C (zh) | 一种抗疱疹病毒的中药制剂及制备方法 | |
CN1301099C (zh) | 地龙滴丸及其制备方法 | |
CN1686434A (zh) | 复方蛤青滴丸及其制备方法 | |
CN1634431A (zh) | 一种治疗上呼吸道感染的银黄滴丸 | |
CN1919238A (zh) | 一种治疗心脑血管病的药物 | |
CN1899388A (zh) | 一种双丹软胶囊及其制备方法 | |
CN1919239A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN1201811C (zh) | 一种治疗近视眼的中药组合物及制法 | |
CN1291727C (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 | |
CN1557403A (zh) | 一种治疗心脑血管疾病的药物及其制备方法 | |
CN1317007C (zh) | 一种珍珠解毒口服液及制备方法 | |
CN1297254C (zh) | 熊胆川贝滴丸及其制备方法 | |
CN1919235A (zh) | 治疗心脑血管疾病的药物组合物 | |
CN1919253A (zh) | 一种治疗心脑血管疾病的药物组合物 | |
CN1965849A (zh) | 从中药中提取用于治疗冠心病的组合物及组分制备方法 | |
CN1682821A (zh) | 复方半边莲滴丸及其制备方法 | |
CN1305493C (zh) | 一种治疗脑中风的中药有效部位及其分离制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: QIANLUCHUN SCIENCE AND TECHNOLOGY CO., LTD., BEIJING Effective date: 20050923 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050923 Address after: 300402 Beichen science and Technology Park, Tianjin Applicant after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 100036, 1, building 1, 1801, Lianhua District, Beijing, Haidian District Applicant before: Qianluchun Tech Co.,Ltd. Beijing |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Beichen science and Technology Park, Tianjin Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Beichen science and Technology Park, Tianjin Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Beichen science and Technology Park, Tianjin Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Beichen science and Technology Park, Tianjin Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CX01 | Expiry of patent term |
Granted publication date: 20070221 |
|
CX01 | Expiry of patent term |